Adaptimmune Therapeutics PLC (ADAP) Stock Rating Upgraded by Zacks Investment Research
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “
Separately, Raymond James Financial Inc. assumed coverage on Adaptimmune Therapeutics PLC in a research note on Friday, September 30th. They set an “outperform” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $15.95.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/adaptimmune-therapeutics-plc-adap-stock-rating-upgraded-by-zacks-investment-research.html
Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded up 3.91% on Monday, hitting $6.65. 169,014 shares of the stock traded hands. The firm has a 50 day moving average price of $7.06 and a 200 day moving average price of $8.43. The firm’s market cap is $470.72 million. Adaptimmune Therapeutics PLC has a 52-week low of $6.19 and a 52-week high of $14.78.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.16. Adaptimmune Therapeutics PLC had a negative return on equity of 21.36% and a negative net margin of 427.33%. On average, equities analysts forecast that Adaptimmune Therapeutics PLC will post ($1.09) EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of ADAP. New Leaf Venture Partners L.L.C. acquired a new position in Adaptimmune Therapeutics PLC during the second quarter worth approximately $1,035,000. Adage Capital Partners GP L.L.C. boosted its position in Adaptimmune Therapeutics PLC by 34.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,550,000 shares of the company’s stock worth $12,633,000 after buying an additional 400,000 shares in the last quarter. Glenmede Trust Co. NA boosted its position in Adaptimmune Therapeutics PLC by 574.9% in the second quarter. Glenmede Trust Co. NA now owns 20,923 shares of the company’s stock worth $170,000 after buying an additional 17,823 shares in the last quarter. Rathbone Brothers plc boosted its position in Adaptimmune Therapeutics PLC by 124.7% in the second quarter. Rathbone Brothers plc now owns 450,525 shares of the company’s stock worth $3,672,000 after buying an additional 250,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Adaptimmune Therapeutics PLC by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock worth $888,000 after buying an additional 3,519 shares in the last quarter. 45.11% of the stock is currently owned by institutional investors.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.